



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

**Date:** May 5, 2009

**To:** Primary Clinical Research Associates

**From:** Janis Wobschall  
Research Protocol Specialist

**Re:** N0572: A Phase I/II trial of Sorafenib and CCI-779 in Recurrent Glioblastoma

The Eligibility Checklist has been revised as follows:

<b>Form Title</b>	<b>Brief Description of Edit</b>
Registration (Step 2) Eligibility Checklist	Assigned Treatment edited to include Arm D

If you have any questions, please feel free to contact me at 507/284-4852.

JW/dg  
Enclosure